HC Wainwright Issues Optimistic Outlook for INO Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Research analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for Inovio Pharmaceuticals in a research report issued on Monday, June 1st. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.26) per share for the quarter, up from their prior forecast of ($0.28). HC Wainwright has a “Neutral” rating and a $2.50 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.01) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.03) EPS and Q4 2027 earnings at $0.07 EPS.

Several other research firms have also recently weighed in on INO. Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th. Finally, Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.25.

Inovio Pharmaceuticals Stock Performance

INO opened at $1.21 on Wednesday. Inovio Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $2.98. The firm has a market cap of $99.55 million, a P/E ratio of -0.83 and a beta of 1.49. The business’s fifty day moving average is $1.29 and its 200-day moving average is $1.62.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares during the last quarter. MCF Advisors LLC bought a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $26,000. Focus Partners Wealth acquired a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $33,000. Raymond James Financial Inc. boosted its holdings in shares of Inovio Pharmaceuticals by 4,396.0% during the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 16,309 shares in the last quarter. Finally, GSA Capital Partners LLP grew its position in Inovio Pharmaceuticals by 3.8% during the 4th quarter. GSA Capital Partners LLP now owns 459,828 shares of the biopharmaceutical company’s stock worth $800,000 after acquiring an additional 16,724 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.